Duke spin-out Aerie Pharmaceuticals sets its pre-IPO price range.

Aerie Pharmaceuticals has set its pre-initial public offering (IPO) price range following the announcement of its intention to float on the Nasdaq as reported in GUV last month.

The Duke University spin-out will be pricing shares between $12-$14 each, has registered 6 million shares, and has a maximum offering price of $85m.

The US-based firm, which is developing therapeutics for eye diseases such as glaucoma, is yet to generate revenue, has raised over $70m in venture backing.

There have…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?